Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Repligen (NASDAQ:RGEN) had its price target increased by investment analysts at Wells Fargo & Company from $180.00 to $185.00 in a research note issued on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the biotechnology company’s stock. Wells Fargo & Company‘s price target points to a potential upside of 31.20% from the company’s previous close.

A number of other equities research analysts have also weighed in on the stock. Canaccord Genuity Group decreased their price objective on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Wolfe Research initiated coverage on shares of Repligen in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $145.00 target price on the stock. Roth Capital began coverage on shares of Repligen in a research report on Friday, April 17th. They set a “buy” rating and a $160.00 target price on the stock. Jefferies Financial Group reaffirmed a “hold” rating and set a $142.00 price target on shares of Repligen in a research note on Tuesday, May 5th. Finally, Benchmark upgraded Repligen from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $166.43.

Repligen Stock Performance

Shares of Repligen stock opened at $141.01 on Thursday. The company has a quick ratio of 7.78, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The stock’s fifty day moving average is $134.66 and its two-hundred day moving average is $131.60. Repligen has a 52 week low of $100.99 and a 52 week high of $175.77. The company has a market capitalization of $7.95 billion, a PE ratio of 193.16, a price-to-earnings-growth ratio of 2.67 and a beta of 1.06.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share for the quarter, topping the consensus estimate of $0.45 by $0.09. The business had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The business’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same period last year, the company earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, analysts expect that Repligen will post 2.06 earnings per share for the current year.

Insider Transactions at Repligen

In other Repligen news, CFO Jason K. Garland sold 733 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $145.00, for a total transaction of $106,285.00. Following the transaction, the chief financial officer owned 19,359 shares of the company’s stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently modified their holdings of the business. AQR Capital Management LLC bought a new stake in Repligen during the 1st quarter valued at $262,000. Jones Financial Companies Lllp increased its holdings in shares of Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock worth $18,067,000 after acquiring an additional 20,375 shares in the last quarter. Bank of Nova Scotia raised its position in shares of Repligen by 88.0% in the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after acquiring an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. lifted its stake in shares of Repligen by 29.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.